AMLX Amylyx Pharmaceuticals Inc
Price (delayed)
$3.34
Market cap
$295.93M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.43
Enterprise value
$219.08M
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a
Highlights
Amylyx Pharmaceuticals's debt has plunged by 53% YoY and by 23% from the previous quarter
The quick ratio has increased by 42% from the previous quarter and by 25% YoY
AMLX's gross profit has dropped by 160% since the previous quarter and by 110% year-on-year
The gross margin has plunged by 146% YoY
Key stats
What are the main financial stats of AMLX
Market
Valuations
Earnings
Shares outstanding
88.6M
Market cap
$295.93M
Enterprise value
$219.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.39
Price to sales (P/S)
2.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.51
Revenue
$87.37M
Gross profit
-$37.26M
Operating income
-$314.73M
Net income
-$301.74M
EBIT
-$302.14M
EBITDA
-$301.23M
Free cash flow
-$167.8M
Per share
Balance sheet
Liquidity
EPS
-$4.43
EPS diluted
-$4.43
Free cash flow per share
-$2.46
Book value per share
$2.4
Revenue per share
$1.28
TBVPS
$2.84
Total assets
$193.63M
Total liabilities
$28.87M
Debt
$1.98M
Equity
$164.77M
Working capital
$161.03M
Debt to equity
0.01
Current ratio
6.67
Quick ratio
6.28
Net debt/EBITDA
0.26
Margins
Efficiency
Dividend
EBITDA margin
-344.8%
Gross margin
-42.6%
Net margin
-345.4%
Operating margin
-360.2%
Return on assets
-101.1%
Return on equity
-127.5%
Return on invested capital
-215%
Return on capital employed
-182.9%
Return on sales
-345.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMLX stock price
How has the Amylyx Pharmaceuticals stock price performed over time
Intraday
-5.65%
1 week
-11.64%
1 month
1.83%
1 year
23.25%
YTD
-11.64%
QTD
-5.65%
Financial performance
How have Amylyx Pharmaceuticals's revenue and profit performed over time
Revenue
$87.37M
Gross profit
-$37.26M
Operating income
-$314.73M
Net income
-$301.74M
Gross margin
-42.6%
Net margin
-345.4%
Amylyx Pharmaceuticals's net margin has plunged by 161% from the previous quarter
AMLX's gross profit has dropped by 160% since the previous quarter and by 110% year-on-year
The company's operating margin has shrunk by 160% QoQ
The gross margin has plunged by 146% YoY
Growth
What is Amylyx Pharmaceuticals's growth rate over time
Valuation
What is Amylyx Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.39
P/S
2.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.51
AMLX's EPS is down by 16% since the previous quarter
AMLX's P/B is 63% above its last 4 quarters average of 0.9
The equity has dropped by 62% year-on-year and by 16% since the previous quarter
The price to sales (P/S) is 130% higher than the last 4 quarters average of 1.2
Amylyx Pharmaceuticals's revenue has plunged by 77% YoY and by 56% from the previous quarter
Efficiency
How efficient is Amylyx Pharmaceuticals business performance
AMLX's return on sales has dropped by 164% since the previous quarter
The company's return on invested capital has shrunk by 55% QoQ
Amylyx Pharmaceuticals's ROE has decreased by 49% from the previous quarter
Amylyx Pharmaceuticals's ROA has decreased by 48% from the previous quarter
Dividends
What is AMLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMLX.
Financial health
How did Amylyx Pharmaceuticals financials performed over time
The company's total liabilities has shrunk by 66% YoY and by 47% QoQ
The total assets has plunged by 63% YoY and by 23% from the previous quarter
Amylyx Pharmaceuticals's debt is 99% less than its equity
The equity has dropped by 62% year-on-year and by 16% since the previous quarter
Amylyx Pharmaceuticals's debt has plunged by 53% YoY and by 23% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.